Skip to content
Acting upon the Food and Drug Administration’s (FDA) request, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) decided unanimously on Thursday to […]
VRBPAC recommends harmonizing COVID vaccines content Read More »
Ahead of the U.S. Food and Drug Administration’s (FDA) meeting to discuss the nation’s COVID-19 vaccine strategy, two studies published Wednesday provide more evidence
Bivalent boosters halve infection, hospitalization risk of XBB variants, studies show Read More »
Australian scientists are a step closer to finding new and more effective treatments for lymphoma and lung cancer after opening up new treatment options
Australian scientists work on helping the immune system kill cancer cells Read More »
Over the last 10 years, partnering has been an essential driver of the U.S. biotech business, with external partnerships increasing by 152% and tripling
Partnering is a big deal at the BIO CEO & Investor Conference in NYC, Feb. 6-7 Read More »
In light of the drastic rebate hike prompted by inflation and COVID-driven increases in demand, the U.K. is no longer a viable market for
European lessons on drug price controls teach the U.S. how ‘not to do it’ Read More »
To simplify and streamline the COVID-19 vaccination process while pushing for increased vaccination rates, the U.S. Food and Drug Administration (FDA) proposed updating the
FDA proposes updating COVID boosters annually Read More »
Rachel King, Interim CEO of the Biotechnology Innovation Organization (BIO), described the organization’s work and goals for 2023 at the Maryland Tech Council (MTC)’s
BIO’s Interim CEO discusses biotech policy, optimism with industry in Maryland Read More »
The U.S. Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) convened a joint session on drug patent systems yesterday.
Patent systems for drugs matter – here’s why Read More »
When the largest private insurance companies use their leverage to save on the cost of prescription drugs, they make it harder for patients to
Excluding drugs from coverage helps PBMs keep profits higher Read More »
Moderna is edging closer to launching a new investigational mRNA vaccine to fight the respiratory syncytial virus (RSV), which was 83.7% effective at preventing
Moderna RSV vaccine is 83.7% effective in Phase 3 trial Read More »
